Global CNS Therapeutics Markets, 2016-2018 & 2024: Patent Expiries of Major Drugs Exert Downward Pressure on the Global CNS Market | Financial Buzz

Global CNS Therapeutics Markets, 2016-2018 & 2024: Patent Expiries of Major Drugs Exert Downward Pressure on the Global CNS Market

Dublin, June 22, 2018 (GLOBE NEWSWIRE) — The “CNS Therapeutics – Global Strategic Business Report” report has been added to ResearchAndMarkets.com’s offering.

The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2016 through 2024. Also, a five-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research.

This report analyzes the worldwide markets for CNS Therapeutics in US$ Million by the following Product Groups:

  • Anti-Alzheimer’s
  • Anti-Parkinson’s
  • Anti-Epilepsy
  • Pain Management
  • Anti-Psychotics
  • Anti-Depressants
  • Others

The report profiles 162 companies including many key and niche players such as:

  • AbbVie Inc. (USA)
  • Alkermes Plc. (Ireland)
  • Allergan, Plc (Ireland)
  • Amneal Pharmaceuticals, LLC (USA)
  • AstraZeneca Plc (UK)
  • BIAL Group (Portugal)
  • Bristol-Myers Squibb (USA)
  • Eisai Co., Ltd. (Japan)
  • Endo Pharmaceuticals Inc. (USA)
  • Eli Lilly and Co. (USA)
  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • Fabre-Kramer Pharmaceuticals, Inc. (USA)
  • GlaxoSmithKline (UK)
  • H. Lundbeck A/S (Denmark)
  • Johnson & Johnson (USA)
  • Janssen Pharmaceuticals, Inc. (USA)
  • Merck & Co., Inc. (USA)
  • Neurocrine Biosciences, Inc. (USA)
  • Novartis AG (Switzerland)
  • Otsuka Pharmaceutical Co., Ltd. (Japan)
  • Pfizer, Inc. (USA)
  • Purdue Pharma L.P. (USA)
  • Sanofi S.A (France)
  • Shire Plc (UK)
  • Strides Shasun Limited (India)
  • Sumitomo Dainippon Pharma Co., Ltd. (Japan)
  • Sunovion Pharmaceuticals, Inc. (USA)
  • Takeda Pharmaceutical Co., Ltd. (Japan)
  • Teva Pharmaceutical Industries Ltd. (Israel)
  • UCB Group (Belgium)

Key Topics Covered:

1. INDUSTRY OVERVIEW
CNS Therapeutics Exhibit Robust Opportunities amidst Rising Incidence of CNS Disorders
List of FDA Approved CNS Drugs: 2015 through 2017
Patent Expiries of Major Drugs Exert Downward Pressure on the Global CNS Market
Patent Expiries of Leading CNS Drugs: 2008-2022
Developed Markets to Maintain their Dominance
Developing Market to Drive the Market Momentum

2. MARKET ANALYSIS BY THERAPEUTIC CATEGORIES
Anti-Epilepsy Market
Global Market Overview
Disease Overview
Treatment
Leading Anti-Epileptic Drugs
Innovative Drugs Needed for Better Treatment Compliance
Abounding Potential for NCEs
Developed Countries Account for a Major Share of Epilepsy Treatment
Developing Countries Struggle with Low Treatment Rates
Refractory Childhood Epilepsy & Pregnancy Epilepsy
Major Concerns
Review of Anti-Epilepsy Drugs
CNS Pain Management
Market Overview
Treatment
Regional Overview
Players
Combination Therapies Gain Prominence
Key Trends in Chronic Pain Management
Minimally Invasive Procedures Gain Popularity for Chronic Back Pain
Neuropathic Pain Management: Market with High Potential
Migraine Market: A Core Vertical in CNS Pain Management
New Pain Management Drugs
Select Pain Management Drugs
Anti-Alzheimer’s
Anti-Parkinson’s
Anti-Depressants
Anti-Psychotics
Other CNS Disorders (ADHD, MS, and Insomnia)
Attention Deficit Hyperactivity Disorder (ADHD)
Multiple Sclerosis (MS)
Insomnia

3. GROWTH DRIVERS & MARKET TRENDS
Burgeoning Global Aging Populace, Longer Life Expectancy to Drive CNS Demand
Increased Spending on Prescription Drugs Bodes Well for the CNS Therapeutics Market
Rising Healthcare Expenditure to Boost CNS Therapeutics Market
Growing Penetration of Generic Drugs Emerges as a Key Trait
Developments in CNS Drug Delivery Technologies Bode Well for the CNS Drugs Market
Understanding of BBB Cell Biology & Its Positive Impact on Epilepsy Drugs: A Case-in-Point
Pharma Companies: Seeking New Tools to Offset Pressure on Drug Pipelines
Awareness Campaigns Launched by Pharma Companies to Benefit the Market
Music and Memory Programs Positively Impact Alzheimer’s Disease (AD) and Related Dementia (ADRD) Patients
New Method to Isolate Active Compounds Related to Alzheimers from Plant Medicines

4. PRODUCT OVERVIEW

5. INNOVATIONS
Scientists Discover New Epilepsy Drug in Fish Model
A Smart Walking Stick for Parkinson’s Patients
New Technologies for Pain Management
A Threat to Opiod Therapeutics
Radiofrequency Ablation Device
Omron Healthcare’s HEAT Pain Pro TENS Device
BurstDR Stimulation from St Jude Medical, Inc
Virtual Reality from DeepStream VR
ActiPatch from BioElectronics Corporation

6. PRODUCT INTRODUCTIONS/INNOVATIONS & R&D BREAKTHROUGHS
Zydus Cadila’s Anti-Depressant Drug Receives USFDA Approval
Neurocrine’s 80 mg INGREZZA Capsules gets FDA Approval
Roche’s OCREVUS gets Swiss Agency Approval
Theranexus’S THN102 Drug Receives US Patent
UCB’s AED VIMPAT gets EU Approval for Paediatric Use
UCB’s AED BRIVIACT Receives Approval from FDA
Dr Reddy’s Unveils Anti-Depressant & Muscle Relaxant Drugs
Sunovion Submits Drug Application to the FDA for Dasotraline
Eisai Pharmaceuticals Unveils Anti-Epilepsy Drug Fycompa
Eisai’s Antiepileptic Drug gets Approval from FDA
UCB’s AED gets EU CHMP Positive Opinion on License Extension
Prexton Unveils Phase II Clinical Testing of its Investigational Drug Candidate in PD
BIAL Introduces New Treatment Opicapone for Parkinson’s Disease
Sunovion’s Latuda Receives FDA Approval to Treat Bipolar Depression
Alkermes gets FDA Approval for Two-Month ARISTADA
Lundbeck & Otsuka’s Brexpiprazole gets Approval from EMA
Sumitomo Dainippon Pharma gets Import Drug License Approval from CFDA
Minoryx’s MIN-102 gets Orphan Drug Designation by FDA
Sunovion’s Latuda gets FDA Approval
Tohoku University Introduces New Drug SAK3
FYCOMPA of Eisai Receives FDA Approval
Proximagen Announces the Meeting of Primary Efficacy Endpoint for Midazolam Nasal Spray
GW Pharmaceuticals Announces Positive Results for Second Phase III Study of Epidiolex
Daiichi Sankyo Reports Results of Two Pain Drugs
Sumitomo Dainippon Pharma Declares Topline Results for Lurasidone from a Phase 3 Study
Ocrevus Receives FDA Approval
FDA Scrutinizes Skin Reactions with Zecuity Sumatriptan Patch
Zinbryta Receives FDA Approval for Treating Multiple Sclerosis
Tecfidera Emerges as a First-line Treatment for Relapsing- remitting Multiple Sclerosis (RRMS)
GlaxoSmithKline Announces the Discontinuation of Retigabine (Trobalt)
EISAI’S BACE Inhibitor E2609 gets Fast Track Designation from FDA
Cleveland Clinic Lerner College of Medicine Unveils NTRX-07
BIAL Introduces Opicapone
iX Biopharma Unveils Next Drug BnoX
Daiichi Sankyo & UCB Unveils Vimpat Tablets
AstraZeneca & Lilly’s AZD3293 gets FDA Fast Track Designation
Eisai Introduces Fycompa (perampanel)
Novartis Drug Afinitor gets EU Approval
TG Therapeutics to Start Phase 2 Clinical Study of TG-1101
Acadia gets FDA Approval for the Nuplazid (pimavanserin) Drug
AstraZeneca & Lilly’s AZD3293 Continues into Phase III of the Phase II/III Seamless Trial
Zambon S.p.A and Newron Unveils Xadago (safinamide)
Lundbeck and Takeda gets CRL from FDA for Brintellix (vortioxetine) sNDA
Allergan Announces Availabilty of VRAYLAR in the US
Otsuka’s gets Approval for ABILIFY
Zambon and Newron Unveils Xadago (safinamide)
UCB gets EU Approval for New Epilepsy Drug BRIVIACT

7. RECENT INDUSTRY ACTIVITY
Mylan Acquires Meda
ProQR Splits Out Amylon Therapeutics for CNS Therapeutics
Allergan Takes Over Lysosomal Therapeutics
AstraZeneca Partners with Takeda
Charles River Takes Over Brains On-Line
Pairnomix Partners with StemoniX to Develop Epilepsy Model
Accera Inks Partnership & Licensing Agreement with DuChemBioH
H. Lundbeck A/S Inks Agreement with IBC
Xenon Takes Over XEN1101
Bristol-Myers Squibb Inks Two Separate Agreement with Biogen & Roche
Valeo Pharma Partners with Zambon
Sumitomo Dainippon Pharma Inks License Agreement with Bukwang
Eisai Inks Agreement with Meiji Seika Pharma
Actavis UK & Ireland Taken Over by Accord Healthcare
Piramal Takes Over Mallinckrodt
Ataxion Takes Over Luc Therapeutics
Otsuka to Take Over Neurovance
nLife Partners with wave life sciences
EISAI Inks Marketing and Distribution Agreement with Orion
Sumitomo Dainippon Pharma Takes Over Tolero
Zydus Cadila Takes Over Sentynl
Takeda Partners with Ovid
Lilly toTake Over CoLucid
Aurobindo Pharma Takes Over Generis
Genkyotex Merges with Genticel
Eisai Inks Agreement with Keio University
Evotec Partners with Celgene
AstraZeneca Inks Agreement with Lilly
Takeda and Lightstone Introduces Cerevance
Pacira Partners with GeneAlign
Allergan Takes Over Chase Pharmaceuticals
Synapcell Partners with University of Utah
BlackThorn Therapeutics to Develop Novel
Evotec Partners with UCB
Ligand Enters License Agreement with Seelos Therapeutics
Takeda Partners with Affilogic
Riemser Takes Over CNS Portfolio from Dolorgiet
OPKO Takes Over Transition Therapeutics, Inc
Sunovion to Take Over Cynapsus Therapeutics
Boehringer Ingelheim Partners with Saniona
Denali Partners with F-star Modular Antibody Technology
Scintilla Takes Over Semnur Pharmaceuticals
Pfizer Takes Over Bamboo Therapeutics
Pfizer Partners with IBM
Lupin Acquires 21 Branded Drugs from Shionogi
Teva Takes Over Actavis Generics
Chronos Takes Over Pre-clinical Programmes from Shire
Otsuka & IBM Inks Agreement to Establish Otsuka Digital Health
Aspen Inks Agreement with AstraZeneca AB and AstraZeneca UK
Merck Acquires Afferent Pharmaceuticals
Centrexion Takes Over three Analgesic Candidates from Boehringer Ingelheim
Reset Partners with Alkermes
Zambon & Newron Pharmaceuticals Expands its Market
Eisai Inks Agreement with Esteve
Upsher-Smith Partners with Saniona
Acorda Agrees to Take Over Biotie Therapies
Eisai Inks Agreement with Sysmex
UCB Inks Agreement with Baylor College
GTCR Partners with Ed Fiorentino
Boehringer Ingelheim Inks Agreement with Arena
PsychoGenics Partners with ADDF
Takeda Inks Agreement with NsGene

8. FOCUS ON SELECT GLOBAL PLAYERS

9. GLOBAL MARKET PERSPECTIVE

Total Companies Profiled: 162 (including Divisions/Subsidiaries 183)

  • The United States (79)
  • Canada (13)
  • Japan (15)
  • Europe (50)
    • France (5)
    • Germany (9)
    • The United Kingdom (9)
    • Italy (2)
    • Spain (3)
    • Rest of Europe (22)
  • Asia-Pacific (Excluding Japan) (19)
  • Middle East (4)
  • Latin America (1)
  • Africa (2)

For more information about this report visit https://www.researchandmarkets.com/research/d3dvkd/global_cns?w=12



CONTACT: ResearchAndMarkets.com
         Laura Wood, Senior Manager
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
         Related Topics: Central Nervous System Drugs 

Primary Logo